Eli Lilly and Company (India) has launched Mounjaro (tirzepatide) in a single-dose vial after receiving marketing authorization from the Central Drugs Standard Control Organisation (CDSCO). Mounjaro is a dual GIP and GLP-1 receptor agonist, designed for chronic weight management and glycaemic control in adults.

The treatment is approved as an adjunct to diet and exercise for adults with obesity (BMI ≥30 kg/m²) or those overweight (BMI ≥27 kg/m²) with at least one weight-related condition. It is also indicated for type 2 diabetes management alongside lifestyle modifications.

Lilly India President Winselow Tucker emphasized the growing burden of obesity and diabetes in India, highlighting the company’s commitment to raising awareness and improving treatment access.

Mounjaro’s efficacy has been established through two major clinical trials:

• SURMOUNT-1: Participants on Mounjaro 15 mg lost an average of 21.8 kg over 72 weeks, compared to 3.2 kg on placebo.
• SURPASS Programme: Showed significant A1C reductions in type 2 diabetes patients using Mounjaro 5 mg, 10 mg, and 15 mg over 40 weeks.

With over 101 million people in India living with diabetes and obesity linked to numerous health risks, Mounjaro offers a promising new treatment to improve metabolic health.